Clinical Trials

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01743989 2021-07-15

ENESTPath

Phase 3 Completed

620 enrolled 26 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00980018 2021-07-01

MACS0999

Phase 4 Completed

52 enrolled 14 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00109707 2021-06-29

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Phase 1/2 Completed

507 enrolled 16 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01844765 2021-04-22

DIALOG

59 enrolled 33 charts 1 FDA

15 enrolled 20 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myeloproliferative Disorders, Neoplastic Processes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01077544 2020-12-29

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Phase 1 Completed

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00471497 2020-11-18

ENESTnd

Phase 3 Completed

846 enrolled 33 charts

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT01274351 2020-09-01

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

112 enrolled 11 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01744665 2020-03-10

ENESTgoal

59 enrolled 18 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00036738 2020-01-29

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

28 enrolled 10 charts

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02115386 2019-12-10

MACS1532

Phase 3 Terminated

7 enrolled 4 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00129740 2019-09-24

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

148 enrolled 9 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02272777 2019-08-19

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

Phase 3 Completed

225 enrolled 7 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02709083 2018-11-02

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Phase 2 Terminated

7 enrolled 5 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02108951 2017-10-27

ENESTswift

Phase 3 Terminated

20 enrolled 17 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00702403 2017-08-10

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Phase 1/2 Completed

40 enrolled 12 charts